Document and Entity Information - USD ($) $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Feb. 27, 2026 |
Jun. 30, 2025 |
|
| Cover [Abstract] | |||
| Document Type | 10-K | ||
| Amendment Flag | false | ||
| Document Period End Date | Dec. 31, 2025 | ||
| Document Fiscal Year Focus | 2025 | ||
| Document Fiscal Period Focus | FY | ||
| Entity Registrant Name | CLIMB BIO, INC. | ||
| Entity Central Index Key | 0001768446 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Shell Company | false | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | true | ||
| Entity Ex Transition Period | false | ||
| Entity File Number | 001-40708 | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Tax Identification Number | 83-2273741 | ||
| Entity Address, Address Line One | 20 William Street | ||
| Entity Address, Address Line Two | Suite 145 | ||
| Entity Address, City or Town | Wellesley Hills | ||
| Entity Address, State or Province | MA | ||
| Entity Address, Postal Zip Code | 02481 | ||
| City Area Code | 866) | ||
| Local Phone Number | 857-2596 | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Title of 12(b) Security | Common Stock, par value $0.0001 per share | ||
| Trading Symbol | CLYM | ||
| Security Exchange Name | NASDAQ | ||
| Entity Common Stock, Shares Outstanding | 47,767,980 | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| ICFR Auditor Attestation Flag | false | ||
| Auditor Name | PricewaterhouseCoopers LLP | ||
| Auditor Location | Seattle, Washington | ||
| Auditor Firm ID | 238 | ||
| Entity Public Float | $ 44.8 | ||
| Documents Incorporated by Reference | DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive proxy statement for its 2026 Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant’s fiscal year ended December 31, 2025, are incorporated by reference into Part III of this Annual Report on Form 10-K. |
||
| Auditor Opinion [Text Block] | Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Climb Bio, Inc. and its subsidiaries (the “Company”) as of December 31, 2025 and 2024, and the related consolidated statements of operations and comprehensive loss, of stockholders’ equity and of cash flows for the years then ended, including the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America. |